Literature DB >> 17619739

Natural history, recurrence, and progression in superficial bladder cancer.

Richard J Sylvester1.   

Abstract

Superficial bladder cancer encompasses patients with stage Ta T1 tumors and patients with carcinoma in situ (CIS). The natural history or treatment-related prognosis of these patients varies considerably from one patient to the next based on the patient's clinical and the tumor's pathological characteristics. Based on a review of the literature, the most important prognostic factors for recurrence are the prior recurrence rate, number of tumors, and tumor size; whereas for progression, the most important prognostic factors are the T category, grade, and presence of CIS. Treatment with intravesical bacillus Calmette-Guerin reduces both the risk of recurrence and the risk of progression, and is the treatment of choice in high-risk papillary tumors and in patients with CIS. Assessment of a patient's prognostic factors and his or her risk of recurrence and progression is a prerequisite for determining the most appropriate treatment and frequency of follow-up for a given patient.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17619739      PMCID: PMC5917231          DOI: 10.1100/tsw.2006.404

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  34 in total

Review 1.  Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.

Authors:  Daher C Chade; Shahrokh F Shariat; Guido Dalbagni
Journal:  Int Braz J Urol       Date:  2009 Nov-Dec       Impact factor: 1.541

2.  Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy.

Authors:  Gui-Ming Zhang; Yao Zhu; Lei Luo; Fang-Ning Wan; Yi-Ping Zhu; Li-Jiang Sun; Ding-Wei Ye
Journal:  Tumour Biol       Date:  2015-06-02

3.  Clinical outcome of primary versus secondary bladder carcinoma in situ.

Authors:  Daher C Chade; Shahrokh F Shariat; Ari Adamy; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2010-06-17       Impact factor: 7.450

4.  Clinical outcomes of primary bladder carcinoma in situ in a contemporary series.

Authors:  Daher C Chade; Shahrokh F Shariat; Guilherme Godoy; Caroline J Savage; Angel M Cronin; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2010-07       Impact factor: 7.450

5.  Downregulation of UPK1A suppresses proliferation and enhances apoptosis of bladder transitional cell carcinoma cells.

Authors:  Haiyan Zhu; Yuxin Tang; Xiangyang Zhang; Xianzhen Jiang; Yong Wang; Yu Gan; Jianfu Yang
Journal:  Med Oncol       Date:  2015-02-21       Impact factor: 3.064

6.  [Quality of care in patients with newly diagnosed bladder cancer: a prospective assessment in northern Germany].

Authors:  C Reek; M Rink; M Bloch; J Hansen; F K Chun; A Schneider; J Busche; M Fisch
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

Review 7.  Combining a molecular profile with a clinical and pathological profile: biostatistical considerations.

Authors:  Richard J Sylvester
Journal:  Scand J Urol Nephrol Suppl       Date:  2008-09

Review 8.  Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?

Authors:  Samir P Shirodkar; Vinata B Lokeshwar
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

Review 9.  The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.

Authors:  Ilhan Karaoglu; Antoine G van der Heijden; J Alfred Witjes
Journal:  World J Urol       Date:  2013-10-29       Impact factor: 4.226

Review 10.  A place for precision medicine in bladder cancer: targeting the FGFRs.

Authors:  Erica di Martino; Darren C Tomlinson; Sarah V Williams; Margaret A Knowles
Journal:  Future Oncol       Date:  2016-07-06       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.